Activation of the PI3K/AKT signaling pathway by ARNTL2 enhances cellular glycolysis and sensitizes pancreatic adenocarcinoma to erlotinib

Abstract Background Pancreatic adenocarcinoma (PC) is an aggressive malignancy with limited treatment options. The poor prognosis primarily stems from late-stage diagnosis and when the disease has become therapeutically challenging. There is an urgent need to identify specific biomarkers for cancer...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Weiyu Ge, Yanling Wang, Ming Quan, Tiebo Mao, Evelyne Y. Bischof, Haiyan Xu, Xiaofei Zhang, Shumin Li, Ming Yue, Jingyu Ma, Haiyan Yang, Lei Wang, Zhengyuan Yu, Liwei Wang, Jiujie Cui
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2024-03-01
Edice:	Molecular Cancer
Témata:	Pancreatic adenocarcinoma ARNTL2 Prognosis Erlotinib Targeted therapy, precision oncology
On-line přístup:	https://doi.org/10.1186/s12943-024-01965-5
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!